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Thai isolates. Only 20 different spoligopatterns were found
among 499 isolates in the Vietnam study, compared to 60
among 244 isolates in our study.
Although the Beijing genotype of M. tuberculosis has been
recognized in settings of emerging drug resistance around the
world, the situation in Southeast Asian countries with a high
frequency of Beijing type isolates appears to be nonuniform.
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Jungle Yellow Fever, Rio de Janeiro
To the Editor: Yellow fever control in Brazil through
vaccination campaigns began in 1937. However, cases of
jungle yellow fever still occur despite the existence of a
potent vaccine and immunization campaigns focused on
areas endemic for the jungle form of the disease (1).
Most of these cases are in men in rural areas.
In Brazil from 1980 to 1998, 376 cases of jungle yellow
fever were laboratory confirmed (by virus isolation, with or
without immunoglobulin [Ig]M-capture enzyme-linked
immunosorbent assay [MAC-ELISA] and immunoperoxi-
dase stain), with 216 deaths (case-fatality rate 57.4%). Most
cases were from Maranhão and Goiás States, with 99 and
41 cases, respectively; Goiás, in midwestern Brazil, reported
a case-fatality rate of 95%.
During 1998 to 1999, 106 cases of jungle yellow fever were
confirmed, with 40 deaths (37.7%). During 1999, 75 cases
were confirmed, compared with 34 cases in 1998 and a mean
of 20 cases per year from 1980 to 1998 (2). In 2000, 84 cases
were confirmed, with 40 deaths (47.6% case-fatality rate).
During 2000, the probable site of infection for nearly all
cases was in Goiás, with 53 confirmed cases and 23 deaths,
suggesting epizootic circulation of the virus (2). These cases
were in unvaccinated persons who became ill in their home
states after traveling to endemic areas for tourism or work.
In Brazil, almost two thirds of the territory is consid-
ered an enzootic area (3). Rio de Janeiro State is not
endemic for jungle yellow fever, but in January 2000, the
Oswaldo Cruz Institute confirmed a case of yellow fever in a
24-year-old woman who had traveled to a national park in
Goiás State on December 28, 1999, with a group of 17 persons.
Yellow fever infections were also confirmed in tourists from
other states who visited this park in late 1999.
The young woman became ill on January 3 with fever,
headache, retroocular pain, prostration, anorexia, and
nausea. She returned to Rio de Janeiro on January 5 and
visited a private clinic on January 7, when a complete blood
count, platelet count, urea, creatinine, liver function tests,
and dengue serologic testing were performed. The patient
had leukopenia (1,730 leukocytes/mm3), 100,000 platelets/
mm3, AST 911 U/L and ALT 680 U/L, creatinine 0.90 mg/
dL, urea 10 mg/dL, and normal bilirubin and protein. Anti-
dengue IgM serology was negative. A blood sample was
collected January 11 for yellow fever diagnosis. Reverse
transcription-polymerase chain reaction (RT-PCR) test was
performed on RNA extracted from the serum (4), and virus
isolation was attempted on C6/36 cells, both with negative
results. A MAC-ELISA test was positive for yellow fever,
with a serum IgM titer 1/80,000 8 days after onset of
symptoms. The patient recovered within a week. After
confirmation of this case in the only person who became ill
in the travel group, yellow fever IgM serologic testing was
performed on the other group members, all of whom tested
negative. RT-PCR and virus isolation were not attempted
because the sera were taken after the viremia period.
Control measures for the Aedes aegypti vector were
promptly taken for a radius of 300 m around the patient’s
home. A vaccination campaign was carried out, during which
735 neighbors were vaccinated. An epidemiologic survey was
conducted in the area by using active surveillance for all
symptomatic cases of fever during the period of yellow fever
transmissibility. Blood samples from patients with fever
were assessed for yellow fever virus and antibodies. Surveil-
lance was intensified immediately in Rio de Janeiro State,
and our laboratory examined 54 sera from patients who had
traveled recently to endemic areas and who had compatible
signs and symptoms (in accordance with a nationwide
protocol). All these persons tested negative for yellow fever.
From January to July 2000, >16.9 million people were
vaccinated against yellow fever (2); however, cases continue
to occur. Unvaccinated persons who visit yellow fever-
endemic areas pose a high risk of introducing jungle yellow
fever cases into nonendemic areas.
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Emergence of Metronidazole-Resistant
Bacteroides fragilis, India
To the Editor: Members of the Bacteroides fragilis group are
the most commonly isolated anaerobic pathogens in
humans. Metronidazole has been the drug of choice for
preventing and treating such infections for 40 years.
Although B. fragilis exhibits the broadest spectrum of
recognized resistance to antimicrobial agents among
anaerobes, the worldwide rate of metronidazole resistance
remains low, <5% (1,2). We report here the first metronida-
zole-resistant strain of B. fragilis from India.
A 34-year-old man with myelodysplastic syndrome was
admitted to our hospital with a short history of myalgia,
general malaise, and bleeding gums. Bone marrow exami-
nation showed evidence of severe aplastic anaemia, for
which he was treated with  cyclophosphamide and blood
transfusions. Ceftazidime and amikacin were also adminis-
tered empirically for febrile neutropenia. The patient
remained in the intensive care unit of our medical oncology
ward and was given repeated courses of chemotherapy and
blood transfusions. He also had repeated episodes of febrile
neutropenia, which resolved with a combination of vanco-
mycin, aminoglycosides, and third-generation cephalospor-
in. After 4 months in the hospital, during an episode of
febrile neutropenia, the patient’s condition started to
deteriorate, and high-grade fever developed. Physical
examination showed temperature of 38°C, heart
rate 80/min, blood pressure 100/70 mmHg, and marked
pallor. Laboratory investigations showed a hemoglobin level
of 4g/dL and marked neutropenia (absolute neutrophil count
320/mm3). Liver and renal function test results were within
normal limits. Peripheral blood smears were negative for
malarial parasites. Culture of urine revealed no growth,
and the Widal test was negative. Two blood samples were
collected in Wampole isolator tubes (Wampole Laboratories,
Cranbury, NJ), for isolation of aerobic and anaerobic
bacteria. Subsequently, intravenous antimicrobial therapy
with vancomycin, metronidazole, and ceftazidime was started.
The patient died a day after collection of blood for culture.
Antemortem blood cultures grew Pseudomonas aerugi-
nosa and B. fragilis. The isolate of B. fragilis was identified
by conventional tests and Rap ID ANA II system  (Innovative
Diagnostic System, Norcross, GA). P. aeruginosa was
sensitive to piperacillin but resistant to amikacin, ceftazi-
dime, cefotaxime, and ciprofloxacin. B. fragilis was resis-
tant to metronidazole (MICs, 256 µg/mL) by both standard
broth dilution method and E-test (AB Biodisk, Solne,
Sweden). The isolate was also resistant to cefotaxime and
ceftazidime. However, it was sensitive to chloramphenicol,
clindamycin, and imipenem.
Primary bacteremia caused by anaerobic organisms
accounts for <5% of septicemia in cancer patients (3).
Chemotherapy is a known predisposing factor for anaerobic
bacteremia because it causes gastrointestinal ulceration,
which permits anaerobes to enter circulation (4).
Anaerobic bacteremia is usually polymicrobial in
etiology and has a high death rate (4). In this case, both
bacterial isolates were resistant to the empirical treatment.
Delay in initiating appropriate therapy was perhaps a
major contributor to the patient’s death.
Metronidazole is the drug of choice for empirical
coverage of anaerobic infections. The precise incidence of
resistance to metronidazole in B. fragilis isolates is difficult
to estimate (5), since routine antimicrobial sensitivity
testing of anaerobes is not being done by most laboratories
in the world. Published articles reveal only a few reported
cases of B. fragilis that were resistant to metronida-
zole (6-10). Although the incidence of resistance to penicil-
lin, cephalosporins, and clindamycin is increasing dramati-
cally, no resistance to metronidazole in B. fragilis was found in
some large-scale studies done throughout the world (11,12).
The true incidence of metronidazole resistance in India
too is possibly underestimated since antimicrobial sensitivi-
ty testing is not being done routinely. However, we are
conducting antimicrobial susceptibility testing of all
anaerobic isolates in our institute. In a previous study we
conducted (13), contrary to this report, none of 32 clinical
isolates belonging to the family Bacteroidaceae obtained
over a 5-year period were resistant to metronidazole.
Recently, the anaerobic reference unit in the UK noted
a possible increase in the incidence of metronidazole
resistance in B. fragilis, an observation that would have
major implications for clinical microbiology laboratories, as
well as for prophylactic and treatment regimens (5).
There is now a growing debate whether in vitro suscep-
tibility testing should be performed for all Bacteroides
isolates to guide antimicrobial therapy. The acquisition of
metronidazole resistance by B. fragilis reported here from
India emphasizes the need for a study to assess more accurate-
ly the susceptibilities of clinical isolates of Bacteroides spp.
Diagnostic microbiology laboratories and clinicians
should be aware that the incidence of metronidazole
resistance in clinically significant anaerobes may be
increasing (5). Since antimicrobial resistance in anaerobes
varies from one hospital to another and between different
geographic locations, all hospitals should survey their
sensitivity patterns and report any emerging resistance.
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